The Therapeutic Effect of Shark Liver Oil in a Rat Model of Acetic Acid-Induced Ulcerative Colitis. 2020

Nastaran Samimi, and Masood Sepehrimanesh, and Omid Koohi-Hosseinabadi, and Reza Homayounfar, and Maral Mokhtari, and Mojtaba Farjam
Noncommunicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran.

Ulcerative colitis (UC) is one of the most well-known types of inflammatory bowel disease that manifests as recurrent inflammation of rectum and colon. The goal of this study is to evaluate the protective effects of shark liver oil (SLO) on acetic acid-induced ulcerative colitis in rats. Eighty induced UC rats were randomly divided into ten equal groups and received the following treatments for seven days: 1 ml of normal saline rectally, 1 ml of gel base (carboxymethyl cellulose) rectally, 10 mg/kg of Asacol rectally, 10 mg/kg of mesalazine orally, 5% gel form of SLO rectally, 10% gel form of SLO rectally, 200 mg of SLO orally, and 400 mg of SLO orally. We examined the oxidative stress indices, histopathological features, and body weight changes, as well as the function of the liver and kidneys at the end of treatment. Administration of 10% rectal and 400 mg oral SLO resulted in a significant weight gain. Also, glutathione peroxidase activity was significantly higher in 5% and 10% SLO-treated groups, and elevated superoxide dismutase activity in rats that received 5% SLO was observed compared to negative control and Asacol groups. While no significant changes were observed in most of the kidney and liver function markers, higher levels of aspartate aminotransferase were detected in the group that received 400 mg SLO orally compared to negative control and Asacol groups. Many histopathological signs of improvement were observed in mesalazine, Asacol, and SLO groups. There were no significant changes detected in the mean rank among different groups. Our data indicate that SLO supplementation could improve the amelioration of acetic acid-induced UC in rats due to its antioxidant effects.

UI MeSH Term Description Entries

Related Publications

Nastaran Samimi, and Masood Sepehrimanesh, and Omid Koohi-Hosseinabadi, and Reza Homayounfar, and Maral Mokhtari, and Mojtaba Farjam
January 1992, European surgical research. Europaische chirurgische Forschung. Recherches chirurgicales europeennes,
Nastaran Samimi, and Masood Sepehrimanesh, and Omid Koohi-Hosseinabadi, and Reza Homayounfar, and Maral Mokhtari, and Mojtaba Farjam
October 2023, Applied biochemistry and biotechnology,
Nastaran Samimi, and Masood Sepehrimanesh, and Omid Koohi-Hosseinabadi, and Reza Homayounfar, and Maral Mokhtari, and Mojtaba Farjam
May 2021, Clinical and experimental pharmacology & physiology,
Nastaran Samimi, and Masood Sepehrimanesh, and Omid Koohi-Hosseinabadi, and Reza Homayounfar, and Maral Mokhtari, and Mojtaba Farjam
January 2022, Archives of medical science : AMS,
Nastaran Samimi, and Masood Sepehrimanesh, and Omid Koohi-Hosseinabadi, and Reza Homayounfar, and Maral Mokhtari, and Mojtaba Farjam
July 2020, Middle East journal of digestive diseases,
Nastaran Samimi, and Masood Sepehrimanesh, and Omid Koohi-Hosseinabadi, and Reza Homayounfar, and Maral Mokhtari, and Mojtaba Farjam
December 1994, Alimentary pharmacology & therapeutics,
Nastaran Samimi, and Masood Sepehrimanesh, and Omid Koohi-Hosseinabadi, and Reza Homayounfar, and Maral Mokhtari, and Mojtaba Farjam
August 2017, The Journal of surgical research,
Nastaran Samimi, and Masood Sepehrimanesh, and Omid Koohi-Hosseinabadi, and Reza Homayounfar, and Maral Mokhtari, and Mojtaba Farjam
June 2017, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,
Nastaran Samimi, and Masood Sepehrimanesh, and Omid Koohi-Hosseinabadi, and Reza Homayounfar, and Maral Mokhtari, and Mojtaba Farjam
February 2024, Inflammopharmacology,
Nastaran Samimi, and Masood Sepehrimanesh, and Omid Koohi-Hosseinabadi, and Reza Homayounfar, and Maral Mokhtari, and Mojtaba Farjam
November 2023, Toxicology mechanisms and methods,
Copied contents to your clipboard!